Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label sotatercept in pediatric pulmonary arterial hypertension
2022-000478-25Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH), sponsored by Merck & Co. Primary endpoint: Serum trough concentration (Ctrough) of sotatercept. Started Oct 2022; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2022-000478-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000478-25.